26 results about "Chronic sinusitis" patented technology

Methods for treating or preventing chronic rhinosinusitis without nasal polyps (CRSsNP) in a subject are provided. Methods comprising administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R) antagonist, such as an anti-IL-4R antibody or antigen-binding fragment thereof, are provided.

The present invention relates to novel heterocyclic compounds useful in the preparation of medicaments for the treatment of diseases associated with various functions of the histamine 4 receptor.In particular, said drugs are useful for treating inflammatory diseases, allergy, pain, nasal polyps, rhinitis, chronic sinusitis, nasal congestion, nasal itching, asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, atopic dermatitis, psoriasis, eczema, pruritus, itchy skin, urticaria, idiopathic chronic urticaria, scleroderma, conjunctivitis, keratoconjunctivitis, ocular inflammation, dry eye, cardiac dysfunction, arrhythmia, atherosclerosis, multiple sclerosis, inflammatory bowel disease (including colitis, Crohn's disease, ulcerative colitis), inflammatory pain, neuropathic pain, osteoarthritis pain, autoimmune disease, thyroid, immune-mediated (also known as type I) diabetes, lupus, post-surgical adhesions, vestibular disorders and cancer.

The invention relates to biodegradable intranasal system for the sustained-release of fluticasone propionate in the intranasal cavity, said system comprising a biodegradable polyester matrix that comprises the fluticasone propionate as the active ingredient to be released in the intranasal cavity, wherein the polyester is selected from the list of poly(L,D-lactic acid) (PLA), poly(caprolactone) (PCL), their copolymers such as PLA-PCL, and mixtures thereof; and a method for preparing said system. The invention also relates to a kit comprising the system of the invention and the means of insertion of the system into the nasal cavity. The invention further relates to fluticasone propionate for use for treating chronic rhinitis or chronic sinusitis, wherein the fluticasone propionate is in a form suitable for administration in the nasal cavity by means of the biodegradable intranasal system of the invention.

The invention belongs to the technical field of biological medicines, and relates to an efficient affinity anti-human IL-33 monoclonal antibody and a preparation method thereof. The monoclonal antibody provided by the invention has good specificity and affinity, accurately targets a key cell factor IL-33, and effectively blocks a binding path between the key cell factor IL-33 and a receptor ST2. As a core factor mediating various inflammatory diseases, such as asthma, allergic dermatitis, chronic sinusitis, chronic obstructive pulmonary disease (COPD) and the like, IL-33 is crucial in intervention of a regulation mechanism for disease treatment. The monoclonal antibody disclosed by the invention is novel in sequence, and provides a new thought for preparation of the medicine by inhibiting IL-33 mediated inflammatory reaction.

Disclosed herein are antigen binding proteins, e.g. an antibody, which bind to IL-5, for use in the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP), wherein the nasal polyps score and / or mean nasal obstruction score is improved.

The invention discloses a medical drug-loading paranasal sinus stent as well as a preparation method and application thereof. The medical drug-loaded paranasal sinus stent comprises a nasosinusitis treatment drug and medical catalyst-free polycaprolactone loaded with the nasosinusitis treatment drug, the drug loading capacity of the medical drug-loading paranasal sinus stent is 2 to 20 weight percent; the 24-hour burst release rate of the medical drug-loading paranasal sinus stent is lt; the continuous release time is more than or equal to 4 weeks; wherein the medical catalyst-free polycaprolactone is prepared by carrying out ring opening polymerization on double ether bond oxalic acid amide dihydric alcohol serving as an initiator and caprolactone. According to the medical drug-loaded paranasal sinus stent, the risk of catalyst residue is completely eradicated from the source, the stent implantation safety is guaranteed, the controllable degradation performance and the drug slow release effect of the stent can meet the paranasal sinus postoperative repair requirement, and the medical drug-loaded paranasal sinus stent is suitable for in-vivo implantation and supporting of people or animals and has important prospects in the field of chronic nasosinusitis postoperative treatment.

A method of treating a patient with of one or more of: allergic asthma; chronic rhinosinusitis with nasal polyps; chronic spontaneous urticaria; nasal polyps; food allergy; moderate to severe persistent asthma in patients with a positive skin test or in vitro reactivity to a perennial aeroallergen and symptoms inadequately controlled with inhaled corticosteroids, the method comprising administering 150 mg / mL omalizumab formulation, wherein the omalizumab is administered subcutaneously by a syringe.

The invention belongs to the technical field of biological medicines, and relates to a monoclonal antibody capable of being specifically combined with IL-33 as well as a preparation method and application thereof. The monoclonal antibody capable of being specifically bound with the IL-33 can be specifically bound with the IL-33 in a high-affinity mode, and therefore binding of the IL-33 and a receptor ST2 of the IL-33 is effectively blocked. IL-33 is an important cell factor, and plays a key role in the occurrence and development of various diseases, such as asthma, specific reactive / allergic dermatitis, chronic sinusitis, chronic obstructive pulmonary disease (COPD) and the like. By blocking the combination of IL-33 and ST2, the antibody can inhibit inflammatory reactions mediated by IL-33, and a new strategy is provided for the treatment of these diseases.

The invention discloses a medicinal moxa composition for preventing and treating chronic nasosinusitis and kidney stone co-disease. The medicinal moxa composition comprises asarum, gardenia jasminoides, agilawood and moxa. The medicinal moxa composition disclosed by the invention generates an external preparation with synergistic effects of smoke, medicinal gas and heating power through combustion. Volatile components of the four medicines are burnt to form a composite pharmacodynamic system which is absorbed by skin, mucous membrane and respiratory system to generate a unique treatment effect. The medicinal moxa composition can realize cold-warm balance, multi-target coordination, immunoregulation, anti-inflammatory action and diuresis metabolism regulation through the synergistic effect of heating power and volatile matters, so that the dual effects of preventing and treating nasosinusitis and kidney stone are achieved. Due to the external use characteristic, the traditional Chinese medicine composition can directly act on body surface acupuncture points and is conducted to related viscera through meridians and collaterals to form a treatment path from the outside to the inside.

This invention belongs to the field of nanomedicine delivery and immunotherapy technology, and provides a treatment for CD4-positive conditions including asthma, inflammatory bowel disease, and chronic sinusitis. + A CD4-targeting Runx3-siRNA nanodelivery system for T-cell-mediated chronic inflammatory diseases comprises lipid nanoparticles loaded with Runx3-siRNA and a CD4-targeting ligand coupled to the surface of the lipid nanoparticles. This system enables targeting of pathogenic CD4-mediated chronic inflammatory diseases. + T-cell-specific delivery and Runx3 gene silencing; lipid nanoparticles composed of ionic lipids, helper lipids, cholesterol, and PEG-modified lipids, with anti-CD4 antibodies anchored to the surface via maleimide-thiol coupling; this invention targets pathogenic CD4... + Specific delivery of T cells and silencing of the Runx3 gene solve the problems of side effects caused by non-specific immunosuppression and insufficient targeting of lipid nanoparticles.

This disclosure describes, inter alia, materials, devices, kits and methods that may be used to treat chronic sinusitis. An implant is configured to fit inside of the middle meatus of a human nasal cavity. The implant includes a therapeutic-agent formulation containing a layer of over 2000 micrograms of mometasone furoate. The implant releases the mometasone furoate for more than 12 weeks. A second implant can also be provided configured to fit inside the middle meatus. The second implant also includes a therapeutic-agent formulation containing a layer of over 2000 micrograms of mometasone furoate, and releases the mometasone furoate for more than 12 weeks.

The invention provides a nasal polyp automatic grading model training method, a scoring method, a system and equipment, and relates to the technical field of image analysis. In order to solve the problem that automatic grading of nasal polyp of a chronic sinusitis patient is difficult to realize in the prior art, an endoscopic image set containing different grades of nasal polyp score marking information is constructed based on nasal endoscopic image data of the patient, and a preset target detection model is trained by using the image set, so that the classification of the nasal polyp of the chronic sinusitis patient is realized. Therefore, the preset target detection model can directly learn and internalize the international standard of nasal polyp grade scoring, and then the preset target detection model can stably learn the nasal endoscope characteristics covering each scoring grade through the full-process training of data enhancement, cross validation and hyper-parameter tuning, so that the accuracy of the nasal endoscopy is improved. And the output nasal polyp grade score has both automation and accuracy, so that the core technical bottleneck of automatic nasal polyp grading under the endoscope is solved.

The invention generally relates to systems and methods for targeting of specific tissue(s) of interest within a sino-nasal region of a patient, specifically sinus regions (i.e., ostia and sinus cavities), for the treatment of chronic sinusitis conditions.

To provide methods for getting data to classify patients with chronic sinusitis, to provide kits for classifying patients with chronic sinusitis, to provide arrays for classifying patients with chronic sinusitis, and to provide apparatus for classifying patients with chronic sinusitis.SOLUTION: One embodiment of the present invention uses the expression of at least three genes contained in a gene cluster consisting of a plurality of specific genes as an index.SELECTED DRAWING: None

The present invention relates to materials, devices, kits and methods for use in treatment of patients having a sinus condition such as severe chronic rhinosinusitis. The implant configured to fit ins

The invention relates to specific polyglycerol derivatives and their further medical uses, namely to dPG / lPG-DTBA and dPG / lPG-cysteamine. These polyglycerol derivatives have a linear or dendritic polyglycerol backbone and carry at least one thiol group covalently bound to the polyglycerol backbone. The claimed medical uses are the use as mucolytic; the use in treating chronic sinusitis, asthma, chronic bronchitis, cystic fibrosis, chronic obstructive pulmonary disease, emphysema, or bronchiectasis; and the use in treating chronic inflammatory bowel diseases, constipation, gastrointestinal malabsorption syndrome, irritable bowel syndrome, steatorrhea or diarrhea.

Disclosed herein, in part, are pharmaceutical compositions comprising dupilumab and arginine-glutamate and methods of using the pharmaceutical compositions to treat medical disorders e.g., atopic dermatitis, eosinophilic esophagitis, prurigo nodularis, asthma, or chronic rhinosinusitis in a patient in need thereof.

The application discloses a dynamic positive and negative pressure coordinated secondary throwing type manual nasal washing device and a use method thereof. The nasal washing device is composed of a main body which is integrally formed of a flexible resilient material, the main body contains an olive-shaped sealing head matched with a nostril and a capsule-shaped head manually extruded, the two are communicated to form a cavity containing a nasal washing liquid, a neck is arranged at the connecting position, a sterile film is arranged at the opening of the sealing head, and the elastic modulus of the main body material is accurately configured. The cavity is pre-filled with a rheological modified nasal washing liquid containing sodium carboxymethyl cellulose, glycerol and hypertonic sea salt. The use method is to generate a pulse type positive pressure by rapid extrusion, release the negative pressure generated by the capsule-shaped head, and repeat the positive and negative pressure operation to realize the circulation and emptying of the secretion. The application realizes the accurate cleaning of the nasal cavity anatomical dead space, significantly improves the biofilm removal efficiency, takes into account the use safety and the mucosa repair effect, is a secondary throwing type design, is simple and convenient to operate and carry, and can be widely applied to the nursing of chronic sinusitis and allergic rhinitis and the postoperative rehabilitation of nasal endoscopy.

The application discloses a nasal secretion biomarker composition for diagnosing type 2 chronic rhinosinusitis with nasal polyps and application thereof, relates to the technical field of biological medicine, and the nasal secretion biomarker composition comprises glial cell-derived neurotrophic factor, cystatin 5, transforming growth factor beta 1 and monocyte chemoattractant protein 4. When the nasal secretion biomarker composition is used for diagnosing CRSwNP intrinsic type, nasal secretion is used as a detection sample, polyp biopsy is not needed, the nasal secretion biomarker composition is non-invasive, simple, convenient, has high sensitivity and specificity, can classify CRSwNP patients before operation without damaging mucosa, can predict the disease intrinsic type of the CRSwNP patient in advance and accurately, and is an ideal non-invasive method.

The present disclosure relates generally to methods of treating chronic rhinosinusitis with or without nasal polyps using antibodies specific for thymic stromal lymphopoietin (TSLP).

The invention relates to a new topical nasal pharmaceutical composition for the treatment and prophylaxis of Rhinosinusitis (RS), comprising a homogeneous aqueous suspension with a therapeutically effective amount of the following well-known active ingredients: Rifamycin, an antibiotic and anti-inflammatory agent for topical or local use; fluticasone propionate, an anti-inflammatory agent for local use; optionally, oxymetazoline hydrochloride, a decongestant; and bacterial antigens, local immunostimulants; 0.9% saline solution, a vehicle; and pharmaceutically acceptable excipients q.s., which are formulated for topical administration via nasal spray. The combination of these compounds produces synergy, resulting in a greater local antibiotic, anti-inflammatory, decongestant and immunomodulatory effect at the specific site of action. Its effectiveness in chronic rhinosinusitis is particularly notable in low doses. So is its good tolerance, absence of adverse effects, and ease of application. No rebound congestion has been reported with prolonged use.

A method of delivering a substance, such as one or more of a triptan, a nasal steroid or carbon dioxide gas, to the nasal cavity of a subject, in particular for the treatment of headaches, for example, migraine, or rhinosinusitis, for example, chronic rhinosinusitis, optionally with polyps, the method comprising the steps of fitting a nosepiece to one nostril of the subject, delivering the substance through the nosepiece to the posterior region of the nasal cavity of the subject.

This disclosure provides a biomarker for prognostic purposes in patients with chronic sinusitis and nasal polyps, which contains a Tuft cell-specific gene or its encoded protein. This biomarker has been validated to have good sensitivity and specificity and can effectively predict the surgical prognosis of patients with chronic sinusitis and nasal polyps.

The invention discloses application of an ADAM8 gene and / or ADAM8 protein in preparation of a medicine for treating chronic sinusitis with nasal polyp and the medicine, and relates to the technical field of biological medicines. According to the application of the ADAM8 gene and / or the ADAM8 protein in preparation of a medicine for treating chronic sinusitis with nasal polyp, the ADAM8 gene and / or the ADAM8 protein are / is used as a treatment target. The research finds that the gene and protein expression level of ADAM8 are obviously up-regulated in ECRSwNP and NECRSwNP and are mainly distributed in inflammatory cells of epithelium and below the epithelium, which prompts that ADAM8 may be a key pathogenic factor in CRSwNP pathogenesis. By specifically inhibiting the activity of ADAM8, nasal polyp-like lesions can be remarkably relieved, infiltration of eosinophilic granulocytes, neutrophil granulocytes and other inflammatory cells can be reduced, key inflammatory signal pathways can be inhibited, collagen deposition and metal matrix protease expression can be reduced, then inflammatory response and a tissue remodeling process can be effectively relieved, and the application of ADAM8 in treatment of nasal polyp-like diseases can be promoted. The scientificity and clinical application prospect of the ADAM8 as a treatment target are verified.

It is provided a method of treatment of a human or animal patient in need thereof to achieve a reduction of the viscosity of mucus of the patient which is carried out by administering a polyglycerol derivative having a linear or dendritic polyglycerol backbone and carrying at least one thiol group covalently bound to the polyglycerol backbone. It is further provided a method of treatment of a human or animal patient suffering from chronic sinusitis, asthma, chronic bronchitis, cystic fibrosis, chronic obstructive pulmonary disease, emphysema, bronchiectasis, chronic inflammatory bowel diseases, constipation, gastrointestinal malabsorption syndrome, irritable bowel syndrome, steatorrhea or diarrhea by administering a polyglycerol derivative. Further specific thiol-functionalized polyglycerol derivatives and a corresponding manufacturing method are provided.